Stoma and Continence Manufacturers

About:

The businesses in this section are all manufacturers of medical devices listed in Part IX A, B and C of the Drug Tariff which are provided to patients via an FP10 prescription through Pharmacy, Dispensing Doctors and Dispensing Appliance Contractors. The membership is made up of small, medium enterprises as well as large multinational organisations. Member companies are represented on the Part IX Industry Drug Tariff Committee, which was formed in the early 1990s to represent companies supplying medical devices through prescription to the public, as listed in Part IX of the Drug Tariff. They are also represented on the PIPs Forum (Patients Industry Professionals Forum), a partnership between Patient Groups, Industry and Professional Groups involved in stoma and continence care, which officially launched in 2001 to address issues and challenges for patients, professionals and industry-working in stoma and continence care. They are also members of the Scottish Stoma Forum which is a national reference group with representatives from patient groups, healthcare professionals and industry.

Aims and objectives:

• We will continue to ensure swift access & adoption of service developments and innovations 
• Utilise national reimbursement systems which facilitate the use of the most appropriate product for the clinical needs of the patient
• We will promote the benefits of the Drug tariff for Part IX products utilising the Part IX Position paper and aim to maintain the prescription route of supply as the route of NHS community provision to patients
• To continue to promote the high-quality products and services that are delivered by manufacturers 

Market information:

Number of companies listed in Part IX A, B, C & R: 460 December 2024

Number of product lines listed in Part IX A, B, C & R: 60,500 December 2024

Market values and growth – 12 months to Dec 2024:

• Stoma £501,916m +6.3%
• Continence £300,721m +6.0%
• Tracheostomy & Laryngectomy £20,594m +7.3%
• Trans Anal Irrigation £41,696m +15.2%
• Total £864,929m +6.6%